Rachelle Suzanne Jacques - 26 Apr 2024 Form 4 Insider Report for Akari Therapeutics Plc (AKTX)

Reporting relationship: Chief Executive Officer, Director
Issuer ticker: AKTX
Reported as of: 26 Apr 2024
Net transaction value: $0
SEC form: 4
Accepted by SEC: 30 Apr 2024, 21:45:06 UTC
Prior SEC filing: 02 Jan 2024
Next SEC filing: 20 May 2024
Source filing: View source filing
Reporting owner signature: /s/ Rachelle Jacques

Key filing fact

Rachelle Suzanne Jacques filed Form 4 for Akari Therapeutics Plc (AKTX) on 30 Apr 2024.

Key facts

This page summarizes Rachelle Suzanne Jacques's Form 4 filing for Akari Therapeutics Plc (AKTX).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 30 Apr 2024, 21:45.

Change

Previous filing in this sequence was filed on 02 Jan 2024.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

AKTX transaction

Ordinary Shares, par value $0.0001 per share

Award

Transaction value: $0
Shares: +479,569,892
Change %: +89%
Price: $0.000000
Shares after: 1,018,027,792
Date: 26 Apr 2024
Ownership: Direct
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

These shares represent restricted stock units ("RSUs"), with each such RSU representing the right to receive one ordinary share, par value $0.0001. 50% of the RSUs shall vest on March 28, 2025, with the remainder vesting in 12 equal monthly installments thereafter, subject to the Reporting Person's continued service with the Issuer on each such vesting date.